CLINICAL TRIALS PROFILE FOR VIBATIV
✉ Email this page to a colleague
All Clinical Trials for VIBATIV
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00061633 ↗ | Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI) | Completed | Cumberland Pharmaceuticals | Phase 2 | 2003-06-01 | Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. One of the ways to deal with this problem is to develop new drugs that can control these bacteria. This study will measure how well TD-6424 (Telavancin) can control infections and whether this drug can be safely given to patients. |
| NCT00061633 ↗ | Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI) | Completed | Theravance Biopharma Antibiotics, Inc. | Phase 2 | 2003-06-01 | Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. One of the ways to deal with this problem is to develop new drugs that can control these bacteria. This study will measure how well TD-6424 (Telavancin) can control infections and whether this drug can be safely given to patients. |
| NCT00062647 ↗ | Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia | Completed | Cumberland Pharmaceuticals | Phase 2 | 2003-08-01 | The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections. |
| NCT00062647 ↗ | Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia | Completed | Theravance Biopharma Antibiotics, Inc. | Phase 2 | 2003-08-01 | The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections. |
| NCT00077675 ↗ | Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI) | Completed | Cumberland Pharmaceuticals | Phase 2 | 2004-02-01 | Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. This study will measure how well TD-6424 (Telavancin) can control infections and whether the drug is safe to give to patients. |
| NCT00077675 ↗ | Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI) | Completed | Theravance Biopharma Antibiotics, Inc. | Phase 2 | 2004-02-01 | Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. This study will measure how well TD-6424 (Telavancin) can control infections and whether the drug is safe to give to patients. |
| NCT00091819 ↗ | Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus | Completed | Cumberland Pharmaceuticals | Phase 3 | 2005-01-01 | Study 0017 compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for VIBATIV
Condition Name
Clinical Trial Locations for VIBATIV
Trials by Country
Clinical Trial Progress for VIBATIV
Clinical Trial Phase
Clinical Trial Sponsors for VIBATIV
Sponsor Name
